← All trials
NCT04015232
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 26, 2018
- Primary completion
- Jun 5, 2018
- Completion date
- Jun 5, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Intas Pharmaceuticals LimitedLead sponsor
- Lambda Therapeutic Research LtdCollaborator
- Lambda Therapeutic Research LtdOverall official - principal investigator
- Intas Pharmaceuticals LimitedStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.